

1.	Record Nr.	UNIORUON00414904
	Autore	DAVES, Charles W.
	Titolo	Samuel Butler (1612-1680) : Characters / edited with an introduction and notes by Charles W. Daves
	Pubbl/distr/stampa	Cleveland and London, : the press of case Western reserve University, 1970
	Descrizione fisica	xiii, 330 p. ; 24 cm.
	Disciplina	820.09
	Soggetti	BUTLER SAMUEL
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
2.	Record Nr.	UNINA9911008938503321
	Autore	Rygiel Katarzyna
	Titolo	The Management of Metastatic Triple-Negative Breast Cancer
	Pubbl/distr/stampa	Sharjah : , : Bentham Science Publishers, , 2023 ©2023
	ISBN	9789815196023 9815196022
	Edizione	[1st ed.]
	Descrizione fisica	1 online resource (263 pages)
	Disciplina	616.99449
	Soggetti	Metastasis Cancer in women
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
	Nota di contenuto	Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- Part 1 -- Unraveling Ethnic Disparities in Triple-Negative Breast Cancer (TNBC): Exploring The

Impact of Metabolic, Reproductive, Environmental, and Social Factors on the Disease Course in African-American (AA) Women Population --

INTRODUCTION -- HOW CAN WE APPROACH ETHNIC DISPARITIES IN TNBC SURVIVAL? - A ROADMAP OF POSSIBLE UNDERLYING BIOLOGIC AND NON-BIOLOGIC RISK FACTORS OR CAUSES OF TNBC IN AA VS. EA (OR NHW) WOMEN -- A SPOTLIGHT ON THE FAMILY HISTORY AND GENETIC MUTATIONS: THE IMPACT OF ETHNICITY ON MOLECULAR MAKE-UP IN TNBC -- SOCIOECONOMIC DISPARITIES IN BC - A LINK BETWEEN THE ECONOMIC DEPRIVATION AND DYSFUNCTIONAL HEALTHCARE PATH -- BEHAVIORAL AND CULTURAL FACTORS ACCOUNTING FOR BC DISPARITIES IN AA WOMEN -- THE UNDERESTIMATED ROLE OF INSUFFICIENT PHYSICAL ACTIVITY AS A RISK FACTOR IN BC DISPARITIES - REFLECTIONS FROM THE SELECTED CLINICAL STUDIES -- IMPACT OF INADEQUATE NUTRITION ON BC DISPARITIES -INSIGHTS FROM MAJOR CLINICAL STUDIES -- CONCLUSION -- REFERENCES --

A Closer Look at the Androgen Receptor (AR)-positive and AR-negative Metastatic Triple-Negative Breast Cancer: Can We Apply Novel Targeted Therapeutics? --

INTRODUCTION -- Various Molecular Subtypes of TNBC -- THE UNDETERMINED PROGNOSTIC VALUE OF ANDROGEN RECEPTOR (AR) IN WOMEN WITH TNBC -- THE INFLUENCE OF ANDROGEN RECEPTOR (AR) ON POTENTIAL THERAPEUTIC CHOICES IN PATIENTS WITH TNBC -- DIFFICULTIES WITH STANDARDIZATION OF ANDROGEN RECEPTOR (AR) TESTING -- TARGETED APPROACHES TO TNBC RESISTANT TO THERAPY: FOCUSING ON "WEAK POINTS" OF AGGRESSIVE CANCERS -- Immune Checkpoint Inhibitors (ICI) (Atezolizumab and Pembrolizumab) -- POLY-ADP-RIBOSE POLYMERASE (PARP) INHIBITORS (OLAPARIB AND TALAZOPARIB) -- Anti-Trop-2 Antibody-drug Conjugate (ADC) (Sacituzumab Govitecan-hziy).

SELECTED ACTIONABLE PHARMACOLOGIC TARGETS AND EMERGING THERAPIES ON THE HORIZON -- CONCLUSION -- REFERENCES --

Liquid Biopsy: Insights Into Monitoring Tumor Dynamics and Response to Therapy in Patients with Breast Cancer --

INTRODUCTION -- HOW LIQUID BIOPSY CAN BE USED IN MONITORING METASTATIC BC PROGRESSION AND TREATMENT? -- TRANSLATING A LEARNING EXPERIENCE FROM THE SOLAR-1 TRIAL INTO CLINICAL PRACTICE: THE APPROVAL OF ALPELISIB AND THERASCREEN -- AN IMPORTANCE OF CTDNA MUTATIONAL ANALYSIS IN THE MANAGEMENT OF PATIENTS WITH METASTATIC BC -- CIRCULATING TUMOR DNA ANALYSIS TO HELP DIRECT THERAPY IN ADVANCED BC (PLASMAMATCH): THE UNIQUE TOOL TO IDENTIFY SENSITIVITY -- AN IMPACT OF THE LIQUID BIOPSY ON THE PERSONALIZED TREATMENT OF WOMEN WITH METASTATIC BC -- Useful Ways of Predicting the Patients' Survival and BC Recurrence -- Can the Circulating Tumor Cell (CTC) Count be Used for a Selection of the First-line Therapy (CHT or ET) in Women with HR-positive, HER2-negative Metastatic BC? -- Can ctDNA Monitoring During the Neoadjuvant Chemotherapy (CHT) Course Reveal a Patient's Risk for Distant BC Metastases? -- Can Lack of ctDNA Clearance in Early Period of Neoadjuvant Chemotherapy (NAC) be a Predictor of Poor Response to Treatment? -- How to Predict the BC Metastatic Relapse Before the Clinical Recurrence? -- CONCLUSION -- REFERENCES --

Importance of Biomarker Conversions as "Road Signs" to Manage Women with Metastatic Breast Cancer: How To Use Them for Personalized Care of These Patients? --

INTRODUCTION -- COMMON CONVERSIONS OF BIOMARKER'S STATUS IN METASTATIC BREAST CANCER -- ALTERATIONS OF THE BIOMARKER'S STATUS IN METASTATIC BREAST CANCER AND THEIR POTENTIAL ROLE IN THE PROGNOSIS AND THERAPY -- COMMON BIOMARKERS OR THEIR COMBINATIONS MATCHED WITH

TARGETED TREATMENTS FOR BREAST CANCER.

BIOMARKERS' SHIFTS IN METASTATIC BREAST CANCER AND THEIR REASSESSMENT: A POTENTIAL ROLE IN THE PROGNOSIS AND TREATMENT -- CONSIDERATIONS OF INTERTUMOR AND INTRATUMOR HETEROGENEITY: CHALLENGES AND OPPORTUNITIES -- Tumor Evolution and Its Connections with Changing of the Biomarker's Status in Metastatic Breast Cancer -- CONCLUSION -- REFERENCES -- Putting It All Together: Clinical Pearls of Recently Approved Therapies for Triple-Negative Breast Cancer -- INTRODUCTION -- A SPECIAL TASK OF PARP INHIBITORS: TARGETING ENZYMES THAT REPAIR DNA DAMAGE -- WHO CAN BENEFIT THE MOST FROM PARP INHIBITORS? - GOOD NEWS FROM THE OLYMPIAD AND THE EMBRACA TRIALS FOR WOMEN WITH METASTATIC BRCA-POSITIVE TNBC -- Shifting Gears to Immunotherapy: Who Can Be A Winner? -- The Role of Ventana and Dako Assay in PD-L1 Testing -- Sacituzumab Govitecan - An Antibody Drug Conjugate (ADC) Starting the "Optimistic Wave" of Therapy for Patients with Metastatic TNBC -- A Spotlight on HER2-low BC: Diagnostic Challenges to HER2 Status Interpretation -- The Remarkable Place of ADCs for Patients with Metastatic TNBC and HER2-low BC -- How to Put Immune Checkpoint Inhibitors and PARP Inhibitors Into Perspective? Considerations of Targeted Therapeutic Options and Their Sequence in Patients with TNBC Associated With the BRCA Mutation and PD-L1 Positivity -- CONCLUSION -- REFERENCES -- The Way Out From the Labyrinth of Anticancer Therapies for Patients with Breast Cancer: How Can We Improve Their Cardiac Safety and Quality of Life? -- INTRODUCTION -- FREQUENT SIDE EFFECTS OF ANTICANCER TREATMENTS AND THEIR PERCEPTION IN PATIENTS WITH BREAST CANCER -- A SPOTLIGHT ON TWO "FACES" OF PAIN SECONDARY TO ANTICANCER THERAPIES IN PATIENTS WITH BREAST CANCER: PERIPHERAL NEUROPATHY AND LYMPHEDEMA. HOW CAN WE APPROACH DEPRESSION AND COGNITIVE IMPAIRMENT IN PATIENTS WITH BREAST CANCER FROM DIFFERENT PERSPECTIVES? -- HOW CAN WE ADDRESS THE MANAGEMENT OF MENOPAUSAL SYMPTOMS IN YOUNGER WOMEN UNDERGOING CHEMOTHERAPY FOR BREAST CANCER? -- HOW TO ASSESS CARDIOTOXICITY RELATED TO TREATMENTS FOR BREAST CANCER? -- MAY STANDARD PHARMACOTHERAPY FOR HEART FAILURE PROVIDE CARDIOPROTECTIVE EFFECTS FOR WOMEN WITH BREAST CANCER? -- HOW TO REDUCE CARDIOTOXICITY RELATED TO TREATMENTS FOR BREAST CANCER? FOCUS ON CARDIO-ONCOLOGY, REHABILITATION, AND INTEGRATIVE INTERVENTIONS -- FURTHER DIRECTIONS: EFFORTS TO DEVELOP THE "KNOWLEDGE NETWORK" FOR PERSONALIZED MEDICINE GOALS -- CONCLUSION -- REFERENCES -- Can We Find A Noninvasive Tool of Precision Medicine That Can Always Be Used For the Individualized Treatment of Women With Breast Cancer? -- INTRODUCTION -- The Goals and Tools of Precision Medicine -- AN EMERGING P4 MODEL: TRANSFORMATION FOR A NEW HEALTHCARE SYSTEM -- A Role of Personomics as A Tool to Fulfill the Unmet Healthcare Needs -- The Alike Initiative: Teaching Personomics In The Academic Setting -- Unique Values of the Patient-centered, "Humanistic" Approach to Medical Management -- Current Possibilities of Personalized Medical Care for Women with Breast Cancer -- COMMON LIMITATIONS OF PERSONALIZED MEDICAL CARE FOR WOMEN WITH BREAST CANCER -- Selected Therapeutic Targets in Advanced or Metastatic TNBC -- CONCLUSION -- REFERENCES -- Part 2 -- Distress - Our "Internal Enemy": How to "Disarm" or Lessen its Negative Impact on the Psychophysical Condition of Women with Triple-Negative Breast Cancer? -- INTRODUCTION -- WHAT CAN PATIENTS WITH CANCER,

CANCER CARE TEAMS, AND CAREGIVERS DO WHEN THE DISTRESS BECOMES VERY SERIOUS? -- Simple Tools to Help Measure Distress. HOW TO TAKE AN ACTIVE ROLE IN PERSONAL MANAGEMENT OF THE CANCER-RELATED DISTRESS AND COOPERATE WITH THE CANCER CARE TEAM? - THE ART OF "DO'S" AND "DON'TS" -- HELPFUL OPTIONS TO MANAGE CANCER-RELATED DISTRESS AND ITS COMPLICATIONS -- CONCLUSION -- REFERENCES -- Teaching the Brain How to Counteract Distress: Practical Lessons About the Stress and Relaxation Responses for Women with Triple-Negative Breast Cancer -- INTRODUCTION -- OPPOSITE PHYSIOLOGIC ACTIONS OF TWO PARTS OF THE AUTONOMIC NERVOUS SYSTEM (ANS) - THE SYMPATHETIC NERVOUS SYSTEM (SNS) AND THE PARASYMPATHETIC NERVOUS SYSTEM (PNS) -- HOW THE PARASYMPATHETIC NERVOUS SYSTEM (PNS) ACTIVATION CAN BE APPLIED TO BENEFIT WOMEN WITH TNBC? -- COMBINING THE AWARENESS ABOUT AUTONOMIC NERVOUS SYSTEM (ANS) SIGNALS WITH INFORMAL APPLICATIONS OF COGNITIVE AND BEHAVIORAL INTERVENTIONS: HOW TO MAKE A POSITIVE TRANSFORMATION? -- ELICITING RELAXATION RESPONSE TO RESTORE A CALMING BALANCE OF THE MIND AND A HEALING POTENTIAL OF THE BODY -- HOW TO TEACH THE BRAIN TO REENGAGE IN THE REPAIR OF SOME STRESS-RELATED DAMAGES? - A THERAPEUTIC "MENU" TO CHOOSE FROM, FOR WOMEN WITH TNBC -- CONCLUSION -- REFERENCES -- An Intersectional Neuroscience Approach for Disadvantageous Populations: Meditation Practice as a Possible Support Option for Women with Breast Cancer? -- INTRODUCTION -- Intersectional Neuroscience (IN) - A Novel Research Model That Can Help Determine Mental States during Meditation in Diverse Populations of Participants -- EVALUATING MULTIVARIATE MAPS OF BODY AWARENESS (EMBODY) - THE INNOVATIVE TASK TO "DECIPHER" MENTAL STATES DURING THE BREATH-FOCUSED MEDITATION -- A POSSIBLE APPLICATION OF THE COMMUNITY-BASED PARTICIPATORY RESEARCH (CBPR) TO INTRODUCE INTERSECTIONAL METHODOLOGY TO BRIDGE THE GAP BETWEEN RESEARCH AND PRACTICE. HOW THE DIFFERENT ATTENTIONAL STATES DURING THE BREATH-FOCUSED MEDITATION CAN BE MEASURED?.

Sommario/riassunto

This comprehensive reference is a timely exploration of two vital aspects of triple-negative breast cancer. The volume offers a holistic perspective and empowering patients to navigate the challenges of triple-negative breast cancer (TNBC) with knowledge and confidence. Understanding Ethnic Disparities and Targeted Therapies: This section provides a critical overview of the ethnic disparities and the latest targeted therapies available for patients facing advanced or metastatic triple-negative breast cancer (TNBC). Empowering Patients and Enhancing Communication: This section dives into the essential role of patient education, empowerment, effective communication with medical teams, and psychological or supportive approaches, providing invaluable insights into managing advanced or metastatic breast cancer (BC). Key Features: Introduces a groundbreaking perspective on the TNBC journey, encouraging patients to view their battle with the disease as an opportunity to leverage modern pharmacological advancements and psychological support for improved outcomes. Bridges the gap between clinical or research-related aspects of BC management and the personal needs and expectations of patients, promoting a more holistic approach. Invites perspectives from a wide range of medical professionals, from oncologists and cardiologists to psychologists and nurses, to engage in open dialogues with patients, offering practical education and crucial support. Provides a wealth of helpful resources (including an appendix) for both patients and their

medical caregivers, fostering a comprehensive and supportive approach to managing TNBC. This book is an informative resource for medical professionals, researchers, and patients, who want to understand the complexities of triple-negative breast cancer and apply current knowledge in their clinical and caregiving practice.
